Utility of routine nurse assessment of the risk of chemotherapy-induced febrile neutropenia

Kelley Moore, Barry Fortner

Abstract


Evidence-based guidelines recommend that patients at high risk (≥ 20%) for febrile neutropenia (FN) should receive prophylactic colony-stimulating factors (Aapro et al., 2006; Kouroukis et al., 2008; National Comprehensive Cancer Network [NCCN], 2008; Smith et al., 2006). We studied the utility of having nurses routinely assess FN risk in new patients before the initiation of chemotherapy. Fifteen nurses used a standardized tool to evaluate FN risk in 150 patients. In 94% of patients studied, nurses detected risk factors that prompted interventions to reduce the incidence of FN. On final evaluation, 67% of nurses said the use of a standardized tool helped them to identify patients at risk for FN, and 73% planned to assess FN risk routinely. Thus, it is feasible and valuable for nurses to assess FN risk using a standardized checklist prior to the initiation of chemotherapy.


Full Text:

PDF

References


Aapro, M.S., Cameron, D.A., Pettengell, R., Bohlius, J., Crawford, J., Ellis,

M., et al. (2006). EORTC guidelines for the use of granulocyte-colony

stimulating factor to reduce the incidence of chemotherapyinduced

febrile neutropenia in adult patients with lymphomas and

solid tumours. European Journal of Cancer, 42(15), 2433–2453.

Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla,

C. (1995). Adjuvant cyclophosphamide, methotrexate, and

fluorouracil in node-positive breast cancer: The results of 20 years

of follow-up. New England Journal of Medicine, 332(14), 901–906.

Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood,

W.C., Weiss, R.B., et al. (1998). Dose and dose intensity as

determinants of outcome in the adjuvant treatment of breast

cancer. The Cancer and Leukemia Group B. Journal of the

National Cancer Institute, 90(16), 1205–1211.

Caggiano, V., Weiss, R.V., Rickert, T.S., & Linde-Zwirble, W.T. (2005).

Incidence, cost, and mortality of neutropenia hospitalization

associated with chemotherapy. Cancer, 103(9), 1916–1924.

Cordonnier, C., Herbrecht, R., Buzyn, A., Leverger, G., Leclercq, R.,

Nitenberg, G., et al. (2005). Risk factors for Gram-negative bacterial

infections in febrile neutropenia. Haematologica, 90(8), 1102–1109.

Dale, D.C. (2002). Colony-stimulating factors for the management of

neutropenia in cancer patients. Drugs, 62(supp 1), 1–15.

Desjardins, B., & Meilleur, M.-C. (2005). Epidemiology of febrile

neutropenia in Canadian provinces: Hospitalization-based

incidence. Presented at the 7th International Symposium on

Febrile Neutropenia, January 27–29, 2005, Seville, Spain.

Donohue, R. (2006). Development and implementation of a risk

assessment tool for chemotherapy-induced neutropenia.

Oncology Nursing Forum, 33(2), 347–352.

Doyle, A. (2006). Prechemotherapy assessment of neutropenic risk.

Oncology Nurse Edition, 20(10, Suppl. 7). Retrieved June 6, 2007,

from http://www.cancernetwork/nurses-edition

Epelbaum, R., Faraggi, D., Ben-Arie, Y., Ben-Shahar, M., Haim, N., Ron,

Y., et al. (1990). Survival of diffuse large cell lymphoma. A

multivariate analysis including dose intensity variables. Cancer,

(6), 1124–1129.

Gaytán-Martínez, J., Mateos-Garcia, E., Sánchez-Cortes, E., González-

Llaven, J., Casanova-Cardiel, L.J., Fuentes-Allen, J.L. (2000).

Microbiological findings in febrile neutropenia. Archives of

Medical Research, 31(4), 388–392.

Johnson, G.D., Moore, K., & Fortner, B. (2007). Baseline evaluation of

the AIM Higher Initiative: Establishing the mark from which to

measure. Oncology Nursing Forum, 34(3), 729–734.

Kouroukis, C.T., Chia, S., Verma, S., Robson, D., Desbiens, C., Cripps,

C., et al. (2008). Canadian supportive care recommendations for

the management of neutropenia in patients with cancer. Curr

Oncol, 15(1), 9–23.

Kuderer, N.M., Dale, D.C., Crawford, J., Cosler, L.E., & Lyman, G.H.

(2006). Mortality, morbidity, and cost associated with febrile

neutropenia in adult cancer patients. Cancer, 106(10),

–2266.

Kwak, L.W., Halpern, J., Olshen, R.A., & Horning, S.J. (1990).

Prognostic significance of actual dose intensity in diffuse largecell

lymphoma: Results of a tree-structured survival analysis.

Journal of Clinical Oncology, 8(6), 963–977.

Lenhart, C. (2004). Performance improvement to ensure

chemotherapy dose delivery. Oncology Supportive Care

Quarterly, 2(4), 6–14.

Lyman, G.H., Dale, D.C., & Crawford, J. (2003). Incidence and

predictors of low dose-intensity in adjuvant breast cancer

chemotherapy: A nationwide study of community practices.

Journal of Clinical Oncology, 21(24), 4524–4531.

Lyman, G.H., Dale, D.C., Friedberg, J., Crawford, J., & Fisher, R.I.

(2004). Incidence and predictors of low chemotherapy doseintensity

in aggressive non-Hodgkin’s lymphoma: A nationwide

study. Journal of Clinical Oncology, 22(21), 4302–4311.

Lyman, G.H. (2005). Guidelines of the National Comprehensive

Cancer Network on the use of myeloid growth factors with

cancer chemotherapy: A review of the evidence. Journal of the

National Comprehensive Cancer Network, 3(4), 557–571.

Lyman, G.H., Lyman, C.H., & Agboola, O. (2005). Risk models for

predicting chemotherapy-induced neutropenia. Oncologist, 10(6),

–437.

Maxwell, C., & Stein, A. (2006). Implementing evidence-based

guidelines for preventing chemotherapy-induced neutropenia:

From paper to clinical practice. Community Oncology, 3,

–536.

National Comprehensive Cancer Network. Myeloid Growth Factors:

The National Comprehensive Cancer Network Clinical Practice

Guidelines in Oncology, version 1.2008. January 2, 2008.

Retrieved August 4, 2008, from http://www.nccn.org

Smith, T.J.C., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage,

J.O., Balducci, L., et al. (2006). 2006 update of recommendations

for the use of white blood cell growth factors: An evidence-based

clinical practice guideline. Journal of Clinical Oncology, 24(19),

–3205.

Vogel, C.L., Wojtukiewicz, M.Z., Carroll, R.R., Tjulandin, S.A., Barajas-

Figueroa, L.J., Wiens, B.L., et al. (2005). First and subsequent cycle

use of pegfilgrastim prevents febrile neutropenia in patients with

breast cancer: A multicenter, double-blind, placebo-controlled

phase III study. Journal of Clinical Oncology, 23(6), 1178–1184.

White, N., Maxwell, C., Michelson, J., & Bedell, C. (2005). Protocols for

managing chemotherapy-induced neutropenia in clinical

oncology practices. Cancer Nursing, 28(1), 62–69.


Refbacks

  • There are currently no refbacks.


Bookmark and Share